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Abstract 
Background: The cardiac isoform of the cystic fibrosis transmembrane conductance regulator 
(CFTR) was shown to be activated by β-adrenergic or purinergic stimulation and involved in 
cell volume regulation after osmotic swelling. Also, cardiac CFTR was reported to be essential 
in the mechanism by which ischemic preconditioning protects against ischemia/reperfusion(I/
R)-induced injury of the heart. Here, we explored the possibility that activation of cardiac 
CFTR can provide protection against I/R-induced myocardial infarction, even after ischemic 
attack. Methods: The hearts of wild-type mice were subjected to 30- or 40-min left coronary 
artery occlusion followed by 2-h or 2-day reperfusion in vivo, and myocardial infarction was 
examined under a variety of conditions. Neonetal rat ventricular myocytes in primary culture 
were subjected to hypoxia/reoxygenation in vitro, and necrotic cell death was examined. 
Results: The infarct size was much greater in CFTR knockout mice than in wild-type mice. 
Intravenous infusion of a number of putative CFTR activators upon reperfusion prominently 
reduced the size of myocardial infarction in wild-type but not CFTR-deficient mice. This 
protective effect was abolished by co-administration of a CFTR inhibitor. CFTR activators 
ameliorated, in a manner sensitive to a CFTR inhibitor, release of myocardial-specific creatine 
kinase isoenzyme to the serum in mice subjected to I/R in vivo. Necrotic death of cultured 
neonatal rat ventricular myocytes subjected to hypoxia/reoxygenation in vitro was ameliorated 
by CFTR activators or CFTR gene overexpression but aggravated by a CFTR inhibitor or CFTR 
gene silencing. Conclusion: It is concluded that activation of endogenous myocardial CFTR 
upon early reperfusion is involved in protection against necrotic myocardial injury induced 
by I/R in vivo and in vitro. Cardiac CFTR may serve as a target accessible even after ischemic 
attack for pharmacotherapeutic intervention in I/R-induced myocardial infarction. 
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Introduction
The cystic fibrosis transmembrane conductance regulator (CFTR) is a Cl− channel 
activated by protein kinase A (PKA) and protein kinase C (PKC), and is a regulator of a number 
of other ion channels [1, 2]. CFTR is principally expressed in a variety of epithelial tissues 
and plays an essential role in transepithelial Cl− and water movement [1]. A splice variant of 
CFTR, in which the product of the 5th exon is deleted, is expressed in cardiac myocytes [3]. 
Electrophysiological studies have provided evidence for functional activation of the cardiac 
CFTR Cl− channel by stimulation of the β-adrenergic receptors [4, 5] and purinergic receptor 
[6]. 
Activation of cardiac CFTR Cl− currents under β-adrenergic stimulation was shown to be 
involved in the hypoxia-induced early shortening of action potentials in perfused and paced 
rabbit hearts [7]. It was also found that under glucose-free hypoxic conditions, molecular 
and functional expression of sarcolemmal CFTR was transiently enhanced in neonatal rat 
ventricular myocytes [8]. Cardiac CFTR Cl− conductance activated by β-stimulation after 
osmotic swelling in isolated guinea pig ventricular myocytes was shown to play an essential 
role in the process of cell volume regulation called regulatory volume decrease (RVD) [9]. 
Persistent cell swelling coupled to impaired RVD has been implicated in the induction of 
necrotic cell death in a number of pathophysiological contexts including ischemia [10]. 
Enhanced RVD due to anion channel-mediated Cl− efflux was actually found to be a key 
mechanism by which ischemic preconditioning (IPC) protects against ischemic cell injury 
in rabbit ventricular myocytes [11, 12]. Furthermore, in isolated mouse hearts subjected to 
ischemia/reperfusion (I/R) insult, cardiac CFTR was shown to be essential for IPC-induced 
protection against necrosis [13] or apoptosis [14] and also for cardioprotection mediated 
by postconditioning (POC) [14]. The question therefore arises as to whether activation of 
cardiac CFTR after ischemic attack can also protect cardiac myocytes against the necrotic cell 
death induced by I/R. The purpose of this study is to answer this question using in vivo I/R 
experiments in the hearts of wild-type (WT) and CFTR knockout (CFTR−/−) mice and using 
in vitro hypoxia/reoxygenation experiments in rat ventricular myocytes in primary culture.
Here, we show that activation of endogenous myocardial CFTR upon early reperfusion 
exerts a protective action, which is unrelated to preconditioning, against necrotic myocardial 
injury by I/R in vivo and in vitro. Cardiac CFTR may serve as pharmacotherapeutic target 
even after an ischemic attack to protect against myocardial infarction. 
Materials and Methods
Animals
Animal experiments were performed in accordance with the guidelines of the Physiological Society 
of Japan. All procedures involving animals were approved in advance by the Ethics Review Committee for 
Animal Experimentation of the National Institutes of Natural Sciences. WT male C57BL/6J mice (9–10 
weeks old) and CFTR−/− B6.129P2-Cftrtm1Unc mice were obtained from CLEA Japan, Inc. (Tokyo, Japan) and 
Jackson Laboratory (ME, USA), respectively, and used in in vivo experiments. Wistar rats were obtained 
from Japan SLC, Inc. (Shizuoka, Japan) and used in in vitro experiments. The animals were housed with 
regulated lighting (light/dark cycle of 12 h/12 h) at 24 ± 1°C. Homozygous CFTR−/− mice were generated by 
mating heterozygous CFTR+/− siblings. Genotyping of littermates was performed by PCR on tail DNA using a 
3-primer assay. To prevent CFTR−/− mice from dying due to ileus, they were fed with a liquid diet (Liquidiet 
F3107: Bioserve, NJ, USA) using glass liquid feeders until 9 to 13 weeks after breast-feeding for 15 days, as 
reported previously [15]. 
Myocardial ischemia/reperfusion in vivo The in vivo experiments were performed using WT and CFTR−/− mice under the constant conditions 
of ~24°C, ~50% moisture and <1005 hPa. The mice were anesthetized with sevoflurane (Maruishi 
Pharmaceutical, Osaka, Japan) vaporized by 20% oxygen and 80% dinitrogen monoxide using a rodent 
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respirator (Model 683: Harvard Apparatus, MA, USA). The temperature around the heart was measured 
by a thermistor and maintained at 36.4 ± 0.4°C by perfusing the thorax with warm saline via an automatic 
temperature controller (TC324B: Warner Instruments, CT, USA). The left coronary artery was ligated with 
an 8-0 silk suture for 30 or 40 min. Ischemia was confirmed by bleaching of the myocardium and the ECG 
pattern monitored via a DEN-751S Amplifier (Unique Medical, Tokyo, Japan). Reperfusion was initiated 
by releasing the ligature and visually confirmed. Reperfusion was continued for 2 h or 2 days. In sham-
operated animals, the suture was placed beneath the left coronary artery without ligation. To administer 
chemical agents, the right cervical vein was cannulated. The test chemicals were administered by a one-shot 
injection of a given dose followed by a 42-min infusion of an additional one-third of the same dose per hour 
(protocol-i in Fig. 1A), by a 12-min infusion of a given dose (protocol-ii in Fig. 1A; protocols in Figs. 2A and 
5A), or by a one-shot injection of a given dose alone (protocol-iii in Fig. 1A), using a syringe for one-shot 
injections and a syringe-pump (KDS-100: Muromachi Kikai, Tokyo, Japan) for continuous infusions.
Infarct size determination
At the end of reperfusion, the left coronary artery was re-ligated in the same location as before, 
and Evans blue dye (1.5%) was infused into the left ventricle from the apex cordis in order to distinguish 
the unstained ischemic zone (i.e., the area at risk) from the blue-stained non-ischemic zone. The heart 
was excised and sliced into 1-mm-thick cross-sections. Ex vivo incubation of the heart sections in 1.5% 
2,3,5-triphenyltetrazolium chloride (TTC: Wako Pure Chemical, Osaka, Japan) for 5 min at 37°C allowed 
differentiation between red-stained viable and pale (unstained) infarcted areas. The left ventricular area 
(LVA), the area at risk (AAR) and the area of infarction (INF) for each slice were measured with ImageJ 
software (NIH, MD, USA). The INF/AAR value was determined and used as a measure of infarct size.
Hemodynamics
Effects of chemical agents on the hemodynamic parameters of the heart were examined during the I/R 
process in a separate group of WT mice. Heart rate and arterial blood pressure were recorded via the left 
groin artery with a disposable transducer (MLT0670: AD Instruments) connected to an amplifier (ML110: 
AD Instruments).
Creatine kinase assay
To monitor myocardial necrotic injury, the level of serum creatine kinase MB isoenzyme (CK-MB) 
of total creatine kinase (CK, EC 2.7.3.2) in blood samples collected via the carotid was measured by the 
immunoinhibition assay using the CK-MB isoenzyme kit (L-Type CK-MB(2): Wako Pure Chemical) and by an 
agarose gel electrophoresis method using the CK isozyme kit (Titan Gel CK: Helena Laboratories, TX, USA). 
The CK-MB values measured by immunoinhibition assay showed a very good correlation (the coefficient: 
r = 0.99749) with those measured by an electrophoresis method (data not shown, n = 6). Therefore, most 
CK-MB measurements were performed by the immunoinhibition assay. The serum was stored at −80°C until 
the measurement and used for assays within one month.
Western blot for in vivo specimens
Hearts were excised from WT mice before and after ischemia induced by ligation of the left coronary 
artery with or without subsequent reperfusion. The left ventricle was then quickly trimmed, frozen in liquid 
nitrogen and powdered. The sample of ~80 mg was immersed in ice-cold lysis buffer containing (in mM) 10 
Tris-HCl (pH 7.3), 1 EDTA, 1 EGTA, 4 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride (an irreversible 
serine protease inhibitor, Pefabloc: Roche Diagnostics, Basel, Switzerland), 0.4 N-(benzyloxycarbonyl)
leucinylleucinylleucinal (a specific, potent, reversible, and cell-permeable proteasome inhibitor, MG132: 
Sigma-Aldrich), 1 sodium orthovanadate (Sigma-Aldrich) and 10 µl/ml protease inhibitor cocktail (Sigma-
Aldrich), and incubated on ice for 30 min. The tissue was then homogenized using a pre-cooled homogenizer 
by repeating 8 strokes 5 times at intervals of 30 s. The same homogenization procedure was repeated 5 times 
more after adding an equal volume of sucrose buffer containing (in mM) 10 Tris-HCl (pH 7.3), 1 EDTA, 1 
EGTA, 500 sucrose, 4 pefabloc, 1 sodium orthovanadate and 10 µl/ml protease inhibitor cocktail. The lysates 
were centrifuged at 3,000×g for 15 min at 4°C, and the supernatants were centrifuged again at 100,000×g for 
30 min at 4°C. The high-speed pellets were dissolved in a 3.5×volume of SDS sample buffer containing 100 
mM DTT (Nacalai Tesque, Kyoto, Japan) and 10 µl/ml protease inhibitor cocktail. After heating at 65°C for 
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3.5 min, the samples were run on a 7.5% SDS-PAGE gel and transferred onto PVDF membranes (Millipore, 
MA, USA). The blocking and reaction with antibody were performed using an advanced ECL kit (Amersham 
Biosciences, NJ, USA). The blots were incubated with rabbit polyclonal anti-CFTR antibodies (Alomone Labs, 
Jerusalem, Israel) overnight at 4°C, and then with horseradish peroxidase-conjugated secondary anti-rabbit 
antibodies (Santa Cruz Biotechnology, CA, USA) for 1 h at room temperature. Enhanced chemiluminescence 
was detected by a Typhoon 9400 (GE Healthcare Biosciences, NJ, USA). The protein assay was performed 
with a 2-D Quant Kit (GE Healthcare Biosciences). As an internal standard for quantitative comparison, Na,K-
ATPase α1 was simultaneously detected using an anti-Na,K-ATPase α1 antibody (Santa Cruz Biotechnology). 
As a positive control for CFTR, rat embryonic heart H9c2 cells transfected with CFTR were employed. H9c2 
cells (ATCC number CRL-1446) were grown in DMEM supplemented with 10% fetal bovine serum and 4 
mM glutamine. Transfection of the pCINeo-IRES-GFP vector containing a CFTR insert into H9c2 cells was 
carried out using both Lipofectamine LTX and PLUS (Invitrogen, CA, USA) according to the manufacturer’s 
instructions. After 48 h of transfection, cells were harvested, dissolved in SDS sample buffer, heated at 65°C 
for 3.5 min, and applied to an SDS-PAGE gel for Western blot.
Ventricular myocytes in primary culture
Primary cultures of neonatal rat ventricular myocytes were prepared as described previously [8]. 
In brief, the hearts were excised from neonatal rats (day 3), and the ventricles were isolated and minced 
in 0.05% trypsin-EDTA. After removing more easily attaching non-myocardial cells, the dissociated cells 
were cultured in Medium 199 (M199: GIBCO-Invitrogen, CA, USA) supplemented with 10% fetal bovine 
serum. To inhibit fibroblast proliferation, bromodeoxyuridine (0.1 mM) was added to the culture medium 
continuously except during the experiment period.
Simulated myocardial ischemia/reperfusion in vitroThe in vitro experiments were performed using cultured rat ventricular myocytes maintained at 37°C 
and 95% air plus 5% CO
2
. After replacing the culture medium with ischemia buffer, the cells were subjected 
to severe hypoxia by placement in a low-oxygen chamber in which air was substituted with argon. Since 
the partial pressure of oxygen (pO
2
) in the ischemic heart in vivo was reported to rapidly reach (within 10 
min) a level of less than 2 mmHg [16], we used ischemia buffer composed of one part oxyrase (Oxyrase 
Inc., OH, USA) and nine parts glucose-free buffer solution containing (in mM) 108 NaCl, 5.4 KCl, 0.5 MgCl
2
, 
5 HEPES and 2.5 Tris (pH adjusted to 7.4 with NaHCO
3
; osmolality adjusted to 300 mosmol/kg-H
2
O with 
mannitol). This hypoxia treatment using oxyrase caused the pO
2
 value, which was monitored by a pO
2
 probe 
(LICOX CMP Monitor: GMS mbH, Mielkendorf, Germany), to fall much more rapidly (to less than 2 mm-Hg 
within 20 min) compared with a hypoxia treatment without oxyrase (to less than 2 mm-Hg after over 200 
min). Reperfusion was performed by replacing ischemia buffer with Dulbecco’s Modified Eagle’s Medium 
(DMEM) containing 1% fetal bovine serum in an incubator equilibrated with 95% air plus 5% CO
2
. Test 
chemical agents were added directly to ischemia buffer and DMEM.
Propidium iodide staining and caspase assay
Necrotic and apoptotic cell death was monitored by propidium iodide (PI) uptake and caspase 3/7 
activation 120 and 300 min after reperfusion, respectively, in cultured cardiomyocytes plated on a 98-well 
plate coated with Cell Matrix (Type I-C: Nitta Gelatin, Osaka, Japan) at a density of 8 × 105/ml at 37°C and 
5% CO
2
. PI staining was performed by incubating the cells with 0.5 µg/ml PI (Dojindo, Kumamoto, Japan) 
and 30 µg/ml Hoechst 33342 for 10 min. The percent of PI-positive cells to total (around 3000) Hoechst 
33342-positive cells was determined with an In Cell Analyzer 1000 (GE Healthcare Biosciences, NJ, USA). 
Caspase 3/7 activity was measured using an Apo-ONE Homogeneous Caspase-3/7 Assay (Promega, WI, 
USA) according to the manufacturer’s instructions. For the positive control, activation of caspase 3/7 was 
induced by applying 4 µM staurosporine (STS) (Sigma Aldrich, MO, USA) for 300 min.
Overexpression of CFTR gene
For CFTR overexpression in neonatal rat ventricular myocytes in primary culture, the vector 
construction was made as previously described [17]. In brief, the coding regions of rat CFTR cDNA were 
subcloned into a bicistronic vector, pCINeo-IRES-GFP. As a negative control, mock transfection was made 
with pCINeo-IRES-GFP vector without CFTR insert. To facilitate the transfection, MATra magnet-assisted 
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transfection system (IBA, Göttingen, Germany) was employed. Cardiomyocytes were seeded on a 96-
well plate coated with Cell Matrix (Type I-C) at a density of 8 × 105/ml. Mixture of DNA (0.4 µg/well), MA 
Lipofection Enhancer reagent (0.2 µl/well) and IBAfect reagent (0.6 µl/well) was prepared according to the 
manufacturer’s protocol. The mixture of 25 µl was add to each well then the culture plates were placed on 
the MATRa magnet plate for 20 min at room temperature. Cells were then kept in the incubator and studied 
on day 3 post-seeding (i.e. 2 days after transfection). 
To assess the effect of transfection with CFTR cDNA in cultured neonatal rat ventricular myocytes, 
immunoblotting was performed. After 48 h of transfection with cDNA of CFTR or vector alone, the 
cardiomyocytes were harvested, dissolved in SDS sample buffer, heated at 65°C for 3.5 min, and applied to 
an SDS-PAGE gel.
Knockdown of CFTR gene
CFTR gene knockdown was performed with small interfering RNA (siRNA) in neonatal rat 
ventricular myocytes in primary culture. Cardiomyocytes were plated on a 96-well plate coated with Cell 
Matrix (Type I-C) at a density of 8 × 105/ml. On day 1 post-seeding, cells were transfected with 25 nM 
siRNA against rat CFTR using HiPerfect transfection reagent (Qiagen, Hilden, Germany) according to the 
manufacturer’s protocol. Gene-specific siRNA against CFTR was purchased from Sigma-Aldrich: sense (5′ 
CUGAUAGUCUUGGUUAUUUTT 3′) and antisense (5′ AAAUAACCAAGACUAUCAGTT 3′). Cells were studied 
on day 3 post-seeding (i.e. 2 days after transfection with siRNA). Fluorescence-labeled non-targeting siRNA 
(ALL STAR: Qiagen) was used as a negative control. In control experiments, almost all cells were found to be 
fluorescence-positive one day after transfection, showing successful transfection.
To assess siRNA-induced changes in the CFTR gene expression in cultured neonatal rat ventricular 
myocytes, semi-quantitative RT-PCR was performed. Total RNA was isolated from control or gene-specific 
siRNA-transfected cells using SEPASOL (Nacalai Tesque, Kyoto, Japan). Contamination of genomic DNA in 
total RNA was removed by treatment with DNase1 (RT-grade: NIPPON GENE, Tokyo, Japan). Total RNA was 
used for synthesis of cDNA using oligo-dT primer (Invitrogen, CA, USA) and GoScript™ Reverse Transcription 
System (Promega). Sequences of primers to amplify rat CFTR and GAPDH as an internal control are as 
follows: CFTR (forward, 5′-ATAGCACACTGAACATCACCG-3′; reverse, 5′-TGAAGAGGCTCAGAGCAAGC-3′), and 
GAPDH (forward, 5′-CATGCCGCCTGGAGAAACCTGCCA-3; reverse, 5′-GGGCTCCCCAGGCCCCTCCTGTTG-3′).
Test chemical reagents 
The following chemicals were applied to test the effects on I/R injury in vivo and/or simulated I/R 
injury in vitro. Genistein was purchased from Wako Pure Chemical (Osaka, Japan), milrinone, gemfibrozil, 
daidzein, and staurosporine (STS) were from Sigma-Aldrich (MO, USA), AG18 (tyrphostin A23) and ICI 
182780 were from Tocris Bioscience (MO, USA) as well as CFTRinh-172 was from Calbiochem (CA, USA), 
and these chemicals were dissolved in DMSO to obtain their stock solutions. Dibutyryl cyclic AMP (dbcAMP) 
(Sigma-Aldrich) and phorbol 12-myristate 13-acetate (PMA: Wako Pure Chemical) were dissolved in 
water and ethanol, respectively, to make their stock solutions. The final vehicle concentrations were less 
than 0.1%. The total doses of genistein, milrinone, PMA, gemfibrozil and CFTRinh-172 given for in vivo 
experiments were 1.2 or 1.5 mg/kg-BW, 50 or 62 µg/kg-BW, 4.8 or 5.9 µg/kg-BW, 43 mg/kg-BW and 0.7 
mg/kg-BW, respectively; and the maximal concentrations they reached in the plasma were calculated to 
be 100 or 123 µM, 2.8 or 3.5 µM, 180 or 222 nM, 1.4 mM, and 20 µM, respectively, if accumulated without 
degradation. The concentrations of these reagents applied for in vitro experiments were as follows: 50 µM 
genistein, 2.8 µM milrinone, 100 nM PMA and 10 µM CFTRinh-172. These concentrations were selected on 
the basis of the pharmacological information, as follows: The reported IC
50
 values of genistein, milrinone, 
PMA, CFTRinh-172, and gemfibrozil are 39.7 µM [18], 2.4 µM [19], 0.01 µM [20], 1.16 µM [21], and 250 µM 
[22], respectively. The reported concentrations for the maximal effects of genistein, PMA, and CFTRinh-172 
are 100 µM [18], 0.1 to 1 µM [23, 24], and 10 to 50 µM [24, 25], respectively. The reported dose for in vivo 
administration via intravenous infusion of milrinone is 50 µg/kg-body weight (BW) for clinical intervention 
in human ischemic disease [26], and that of CFTRinh-172 is 0.6 to 3 mg/kg-BW for antidiarrheal efficiency 
in rodents [27]. It must be noted that the blocking effect of CFTRinh-172 was reported to be selective to 
the CFTR channel compared to other types of anion channel [28], but was not so far examined about its 
selectivity against cardiac cation channels, as done for another CFTR inhibitor, GlyH-101 [29]. Since the IC
50
 
value of AG18 for tyrosine kinase inhibition and the effective concentration to inhibit a chloride channel 
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were reported to be 62 µM [30] and 100 µM [31], respectively, AG18 was applied for the present in vitro 
experiments at 100 µM.
Statistical analyses
Data are expressed as means ± SEM and were analyzed with the SPSS software package (11.0J: SPSS 
Japan Inc., Tokyo, Japan). For in vivo data, statistical multiple comparisons were performed by Peritz’s 
closed testing procedure with the Kruskal-Wallis H statistic. Significance was judged so that the overall 
experimentwise error rate became <0.05. For in vitro data, one-way ANOVA analysis followed by the post-
hoc Dunnett’s t test was performed among multiple groups, and t-test was performed between two groups.
Results
Myocardial ischemia/reperfusion injury in vivo is ameliorated by CFTR activators 
administered upon reperfusion
To examine a possible role of CFTR during a time period that included 10-min pre-
ischemia, 30-min ischemia and 2-min early reperfusion phases, we first observed the 
effects of intravenous administration of CFTR activators by a one-shot injection followed 
by a 42-min continuous infusion of CFTR activators on I/R injury, as shown in the in vivo 
experimental protocol given in Fig. 1A (protocol-i). The isoflavonoid genistein (1.5 mg/kg-
body weight (BW)), which is known to activate CFTR anion channels in cardiomyocytes [32, 
33], markedly decreased the myocardial infarction (pale area unstained with TTC) produced 
by 30-min ischemia followed by 2-day reperfusion (Fig. 1B). Co-administration of an inhibitor 
of phosphodiesterase type III (PDEIII), milrinone (62 µg/kg-BW), which should increase 
intracellular cyclic AMP thereby stimulating PKA, and a PKC activator, phorbol 12-myristate 
13-acetate (PMA: 5.9 µg/kg-BW), also provided prominent protection of the ventricle from 
I/R injury (Fig. 1B). As quantitatively summarized in Fig. 1C, genistein reduced the infarct 
size assessed by INF/AAR by half, and milrinone plus PMA reduced it by one third, without 
significantly affecting the ratio of the area at risk to the left ventricular area (AAR/LVA) in 
either case (Table 1). 
There are several time periods during which these chemicals exerted a protective 
action on the ventricle from I/R injury: the 10-min pre-ischemia, 30-min ischemia, early 
reperfusion, and late reperfusion phases. To discriminate amongst the possibilities, we next 
compared the effects of milrinone plus PMA administered by protocol-i with the effects 
of the same chemicals at an 80% dose administered by a 12-min infusion starting 10 min 
before reperfusion (protocol-ii: Fig. 1A), and by a one-shot injection given 10 min after 
starting reperfusion (protocol-iii: Fig. 1A). As summarized in Fig. 1C, protocol-ii resulted 
Table 1. The ratio of area at risk per left ventricular area (AAR/LV: %). Data are given as mean ± SEM. 
All the data administered with chemicals are not significantly different from the vehicle data (Dunnet-t test; 
p > 0.05).
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in a protective effect similar to that of protocol-i, without significantly affecting the AAR/
LVA value (Table 1), whereas protocol-iii exhibited no protective effect. Since the chemicals 
administered by protocol-ii may not reach the tissue site during the ischemic period but may 
reach it only after reperfusion, these data indicate that the early reperfusion phase is the 
time period during which the tissue site is sensitive to these chemicals.
Fig. 1. Effects of intravenous 
administration of CFTR activators 
on myocardial I/R injury in vivo 
in WT mice. (A) Experimental 
protocols. At end of 2-day 
reperfusion, infarct size was 
measured after staining with TTC. 
Chemicals were intravenously 
applied by a one-shot injection 
followed by continuous infusion 
(protocol-i), by a continuous 
infusion (protocol-ii) or by a one-
shot injection (protocol-iii). (B) 
Representative cross-sections of 
TTC-stained left ventricles from 
animals administered vehicle 
alone, genistein or milrinone 
plus PMA by protocol-i. (C) 
Mean infarct size, calculated 
as the INF/AAR values (± SEM: 
bar; n = 6–16), after treatment 
with vehicle alone, genistein or 
milrinone plus PMA administered 
by protocol-i, and by protocol-ii 
and protocol-iii for milrinone plus 
PMA. *p < 0.05 and NS: p > 0.05 
between two data designated.
Fig. 2. Effects of intravenous 
administration of a CFTR 
activator (genistein) and a CFTR 
inhibitor (CFTRinh-172 or 
gemfibrozil) on myocardial I/R 
injury in vivo in WT and CFTR−/− 
mice. (A) Experimental protocol 
employed in this experiment. At 
end of 120-min reperfusion, the 
hearts were stained with TTC. 
(B) Representative cross-sections 
of TTC-stained left ventricles 
of WT mice and CFTR−/− mice 
administered genistein or 
CFTRinh-172 under I/R. (C and 
D) Mean infarct size, calculated 
as the INF/AAR values (± SEM: 
bar; n = 7–16 for C and 7–8 for D), 
after treatment with vehicle alone 
and chemicals in WT mice (C) and 
CFTR−/− mice (D). *p < 0.05 vs the 
vehicle data in WT mice.
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Endogenous myocardial CFTR activity is involved in protection against ischemia/
reperfusion injury in vivo
Genistein (1.2 mg/kg-BW) administered by a 12-min infusion again markedly 
protected against myocardial infarction produced by 40-min ischemia followed by 120-min 
reperfusion in vivo (protocol shown in Fig. 2A), as shown in Fig. 2 (B and C). In contrast to 
genistein, a 12-min infusion with gemfibrozil (43 mg/kg-BW), which is a blocker of the CFTR 
channel [22], significantly increased the infarct size (Fig. 2C) without significantly affecting 
the AAR/LVA value (Table 1). Another CFTR inhibitor, 3-[(3-trifluoromethyl)phenyl]-5-
[(4-carboxyphenyl)methylene]-2-thioxo-4-thiazolidinone (CFTRinh-172, 0.7 mg/kg-BW), 
similarly aggravated I/R injury (Fig. 2, B and C) without significantly affecting the AAR/
LVA value (Table 1). Administration of CFTRinh-172 did not induce myocardial infarction 
Fig. 3. Effects of intravenous administration of genistein and milrinone plus PMA on time-dependent 
changes in blood pressure and heart rate in mice subjected to I/R in vivo. (A) Blood pressure. (B) Heart 
rate. Insets: Experimental protocol employed in this experiment. Error bars represent SEM (n = 4–5). *p 
< 0.05 vs the vehicle data at a given time point. It is noted that time-dependent changes in blood pressure 
were not significantly affected by genistein or milrinone plus PMA (A), and that those in heart rate were not 
significantly affected by genistein (B, triangles). Milrinone plus PMA slightly induced an enhancing effect on 
the heart rate, though the effect was statistically significant only at 60 and 105 min (B, circles).
Fig. 4. Effects of ischemia and ischemia/reperfusion 
in vivo on molecular expression of CFTR in the 
ventricles of WT mice. (A) Representative Western 
blot data for CFTR protein and Na,K-ATPase α1 in 
mouse ventricles before (0 min) and 30 or 40 min 
after ischemia, followed by no reperfusion or 5- 
or 10-min reperfusion. The last lane shows CFTR 
protein signal derived from H9c2 cells transfected 
with CFTR, which serves as a positive control. (B) 
The mean values (± SEM, n = 4) for relative intensity 
of the CFTR bands, normalized with Na,K-ATPase α1 
band intensity. There are no significant difference 
between the data at given time points and the data 
at 0 min.
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in sham-operated mice (data not shown, n = 3). Furthermore, CFTRinh-172 completely 
eliminated the protective effect of genistein (Fig. 2C) with little effect on the AAR/LVA 
value (Table 1). These pharmacological data support the idea that activation of endogenous 
myocardial CFTR anion channels upon early reperfusion protects against I/R injury in vivo. 
To avoid ambiguousness associated with pharmacological approaches, an involvement 
of CFTR endogenously expressed in the mouse heart in vivo was next studied by employing 
CFTR−/− mice. As shown in Fig. 2 (B and D), the infarct size in CFTR−/− mice administered 
vehicle alone was greater than that in WT mice administered vehicle alone, and reached a 
size similar to that in WT mice administered a CFTR blocker (Fig. 2C). Moreover, genistein 
failed to protect against I/R injury in CFTR−/− mice (Fig. 2, B and D), indicating that the actual 
target of genistein was CFTR under the present experimental conditions. 
To examine the possibility that the protective effects of genistein and milrinone plus 
PMA were mediated by changes in the hemodynamics of the heart, blood pressure and heart 
rate were continuously monitored during a period of 40-min ischemia followed by 120-
min reperfusion, with administration of CFTR activators by a 12-min infusion starting 10 
min before reperfusion (protocol: see Insets in Fig. 3). Time-dependent changes in blood 
pressure were never significantly affected by genistein or by milrinone plus PMA (Fig. 3A). 
Although the heart rate was slightly enhanced after a 12-min infusion of milrinone plus PMA, 
that was not significantly affected by genistein (Fig. 3B). These data suggest that the target of 
these chemicals is myocardial CFTR. Actual expression of the myocardial CFTR protein before 
and after ischemia/reperfusion was confirmed by Western blot (Fig. 4). The CFTR protein 
expression never decreased but rather tended to increase by 30 to 40 min of ischemia, and 
the expression level did not significantly decrease even after 5 to 10 min of reperfusion (Fig. 
4). 
Taken together, these results are in agreement with the inference that the activity of 
myocardial CFTR endogenously expressed in the mouse heart is involved in protection 
against I/R injury in vivo.
Myocardial CFTR activity ameliorates necrotic injury induced by ischemia/reperfusion in 
vivo
Since ischemic myocardial necrotic injury is known to be reflected by increased serum 
activity of the myocardial-specific isoenzyme of creatine kinase (CK-MB) [34, 35], the level 
of serum CK-MB was measured after I/R in WT mice in vivo in the absence and presence 
of CFTR activator or inhibitor using the experimental protocol shown in Fig. 5A. Sham-
operation per se was found to increase the serum CK-MB activity up to around 46000 IU/l 
Fig. 5. Effects of intravenous administration of a 
CFTR activator (genistein) and a CFTR inhibitor 
(CFTRinh-172) on the release of CK-MB to the blood 
plasma in WT mice subjected to I/R or a sham 
operation. (A) Experimental protocol employed in 
this experiment. At the end of 180-min reperfusion, 
the serum level of CK-MB was measured. (B) The 
mean values for increased serum CK-MB activity 
(± SEM; n = 3–7) after sham-operation or I/R 
with treatment with vehicle alone, genistein or 
CFTRinh-172. The serum CK-MB activity of normal 
mouse under anesthesia was 224.8 ± 117.1 IU/l 
(n = 5). Serum CK-MB activities were measured by 
the immunoinhibition assay. *p < 0.05 vs the Sham 
data. (C) The INF/AAR values (± SEM; n = 6) of mice 
from which serum samples were obtained for CK-MB 
measurements. * p < 0.05 vs the vehicle data.
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from the normal level (around 225 IU/l), as summarized in Fig. 5B (Sham), in agreement 
with previous reports that CK-MB release was induced by heart surgery, such as coronary 
bypass grafting and thoracotomy, even in patients in the absence of myocardial infarction 
[36-38]. After 40-min ischemia followed by 180-min reperfusion in vivo (protocol shown 
in Fig. 5A), the serum level of CK-MB further increased, as shown in Fig. 5B (Left), in WT 
mice administered vehicle alone. Necrotic CK-MB release was reduced to the level of sham-
operation by administration of genistein (1.2 mg/kg-BW) by a 12-min infusion starting 10 
min before reperfusion (Fig. 5B, Middle). Infusion of CFTRinh-172 (0.7 mg/kg-BW for 12 
min) caused a more marked increase in the serum CK-MB activity in mice subjected to I/R 
compared to that observed in sham-operated mice administered CFTRinh-172 for 12 min 
(Fig. 5B, Right). The serum CK-MB levels after I/R with infusion of vehicle, genistein and 
CFTRinh-172 well correlated with the INF/AAR values (Fig. 5C).
Myocardial CFTR activity ameliorates necrotic injury induced by hypoxia/reoxygenation 
in vitro
Necrotic cell injury was also monitored by PI uptake in cultured neonatal rat 
cardiomyocytes in primary culture under simulated I/R in vitro, using the experimental 
protocol depicted in Fig. 6A. After 60-min hypoxia followed by 120-min reoxygenation, 
the % of PI-positive necrotic cells increased from the baseline value (7.2 ± 0.4%, n = 3) to 
approximately 15% (Fig. 6B, vehicle). However, the necrotic cell injury induced by hypoxia/
reoxygenation was reduced to around 8% by a 45-min treatment (from 15 min before to 
30 min after reoxygenation) with genistein (50 µM). Genistein is known to exhibit not only 
a CFTR-activating effect but also a weak estrogenic effect due to estrogen receptor binding 
[39] and an inhibitory effect on protein tyrosine kinases (PTKs) [40]. However, a selective 
estrogen receptor antagonist, ICI 182780 (10 µM), failed to affect hypoxia/reoxygenation-
induced necrosis of cultured cardiomyocytes and to eliminate the ameliorating effect of 
Fig. 6. Effects of extracellular application of chemicals on hypoxia/reoxygenation-induced necrosis and 
apoptosis in cultured neonatal rat ventricular myocytes. Following chemicals were applied: a CFTR activator 
(genistein, daidzein, milrinone plus PMA or dbcAMP plus PMA), a CFTR inhibitor (CFTRinh-172), an 
estrogen receptor antagonist ICI 182780 (ICI), a protein tyrosine kinase inhibitor (AG18) and an apoptosis 
inducer (STS). (A) Experimental protocol employed in this hypoxia/reoxygenation experiment. (B) The % 
of PI-positive necrotic cells measured at the end of 120-min reoxygenation. (C) The caspase 3/7 activity 
(expressed by relative fluorescence units: RFU) measured at the end of 300-min reoxygenation. (D) The 
positive control caspase 3/7 activity in cultured cardiomyocytes treated with 4 µM STS for 300 min. Values 
are means ± SEM (n = 9–18 for B, 8 for C and 3 for D). * p < 0.05 and ** p < 0.001 vs the vehicle data.
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genistein when applied together (Fig. 6B, ICI). Also, a PTK inhibitor, AG18 (100 µM), failed 
to mimic the genistein effect (Fig. 6B). Furthermore, the genistein effect was mimicked by 
daidzein (75 µM) (Fig. 6B), a structural analog of genistein that has little inhibitory effect on 
PTKs but is capable of activating CFTR anion channels [33]. Thus, it appears that genistein 
protects against hypoxia/reoxygenation in vitro through its action on CFTR channels but 
not through effects on estrogen receptors or PTKs. Actually, a similar protective effect was 
induced by treatment with other CFTR-activating chemicals, milrinone (0.6 µg/ml) plus PMA 
(100 nM) and dibutyryl cyclic AMP (dbcAMP) (1 mM) plus PMA (100 nM), as summarized in 
Fig. 6B. Also, treatment with a CFTR inhibitor, CFTRinh-172 (10 µM), increased the number 
of PI-positive cells to approximately 20% and totally eliminated the ameliorating effects of 
genistein and milrinone plus PMA (Fig. 6B). The activity of caspase 3/7 measured 300 min 
after reperfusion was not affected by genistein, dbcAMP plus PMA or CFTRinh-172 (Fig. 6C), 
although treatment with an apoptosis inducer STS (4 µM for 300 min) activated caspase 3/7 
in cultured neonatal rat cardiomyocytes (Fig. 6D). 
To directly demonstrate an involvement of CFTR in cultured rat cardiomyocytes, the 
effects of transfection with cDNA of or siRNA against CFTR were observed under simulated 
I/R using the experimental protocol given in Fig. 7A. Necrotic cell injury induced by hypoxia/
reoxygenation was ameliorated by overexpression of CFTR gene (Fig. 7B). In contrast, 
simulated I/R-induced necrotic cell injury was aggravated by CFTR gene silencing (Fig. 7C)
Taken together, it is concluded that the activation of myocardial CFTR anion channels 
may protect against necrotic, but not apoptotic, injury induced by I/R in vivo and by simulated 
I/R in vitro.
Discussion
Molecular remodeling of a number of ion channels including CFTR is known to be 
induced in cardiac myocytes subjected to ischemic cardiomyopathy [41]. In fact, our previous 
study demonstrated that molecular and functional expression of cardiac CFTR did not 
decrease but becomes transiently upregulated by simulated ischemia in vitro in neonatal rat 
ventricular myocytes in primary culture [8]. Also, in the present study, molecular expression 
of the cardiac CFTR protein was found to never decrease but tend to be enhanced in vivo in 
the mouse ventricle after ischemia (Fig. 4). 
Genistein, which is the best-studied potentiator of CFTR activity [33], effectively 
reduced I/R injury in vivo in the mouse heart (Figs. 1 and 2) and simulated I/R injury in 
vitro in rat cardiomyocytes (Fig. 6). The in vivo genistein effect was found to be abolished 
Fig. 7. Effects of overexpression and knockdown 
of CFTR gene on hypoxia/reoxygenation-induced 
necrosis in cultured ventricular myocytes. (A) 
Experimental protocol employed in this hypoxia/
reoxygenation experiment. (B and C) At the end 
of 120-min reoxygenation, the % of PI-positive 
necrotic cells were measured in cultured neonatal 
rat ventricular myocytes transfected with WT CFTR 
cDNA (B, bottom panel) and CFTR siRNA (C, bottom 
panel). Transfection efficiency was tested for CFTR 
cDNA by Western blotting (B, upper panel) and 
for CFTR siRNA by RT-PCR (C, upper panel). Na,K-
ATPase α1 and GAPDH were analyzed as loading 
controls. Values are means ± SEM (n = 8 for B and 
9 for C). ** p < 0.001 vs mock (B) and * p < 0.05 vs 
control (C).
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by a CFTR channel inhibitor, CFTRinh-172 (Fig. 2C). Also, as shown in Fig. 6B, the protective 
effect of genistein on hypoxia/reoxygenation-induced injury in vitro in rat cardiomyocytes 
was eliminated by CFTRinh-172 and was not mimicked by an estrogen receptor antagonist, 
ICI 182780, or a PTK antagonist, AG18. It could, however, be mimicked by a genistein analog, 
daidzein, which is known to activate CFTR and not inhibit PTKs. Moreover, genistein failed 
to affect I/R injury in vivo in CFTR-deficient mice (Fig. 2D). These results indicate that the 
target of genistein is cardiac CFTR. 
Putative PKA and PKC phosphorylation sites are highly conserved in both the epithelial 
and cardiac isoforms of CFTR, and synergistic interactions between PKA- and PKC-mediated 
phosphorylation play an important role in the activation of epithelial [42] and cardiac CFTR 
[43]. In the present study, the combined application of a PDEIII inhibitor, milrinone, and a 
PKC activator, PMA, was found to reduce I/R-induced myocardial infarction in vivo (Fig. 1) 
and hypoxia/reoxygenation-induced cardiomyocyte death in vitro (Fig. 6). The protective 
effect of milrinone plus PMA in vitro was abolished by CFTRinh-172 and was mimicked 
by dbcAMP plus PMA (Fig. 6). This effect of milrinone on cardiac CFTR may well explain 
previous observations that pre-ischemic administration of milrinone protects against I/R-
induced myocardial injury [44, 45]. 
CFTR is known to be expressed in vascular smooth muscle cells and to regulate vascular 
tone in a manner dependent on cyclic AMP [46]. Thus, there is a possibility that activation 
of vascular CFTR is involved in protection against I/R injury. However, in the present study, 
blood pressure was not affected by administration of CFTR activators (Fig. 3). Also, the 
protective effects of CFTR activators were reproduced in vitro in the simulated I/R system 
that used cultured cardiomyocytes and was devoid of vascular smooth muscle cells (Fig. 6).
It seems likely that endogenous activity of CFTR protects against I/R injury even 
without the administration of any CFTR activators, because a CFTR blocker (gemfibrozil or 
CFTRinh-172) aggravated I/R-induced myocardial infarction in vivo (Fig. 2) and hypoxia/
reoxygenation-induced cardiomyocyte death in vitro (Fig. 6), though one cannot completely 
exclude possible non-specific actions of these CFTR activators and blockers. However, the 
present study showed that myocardial infarction observed in the ventricle of CFTR-deficient 
mice in vivo was more marked than that in the WT mice (Fig. 2), directly supporting 
an involvement of endogenous CFTR in the protection effect. A similar involvement of 
endogenous CFTR in cardioprotection against I/R injury was also shown for IPC in the in vivo 
models [13, 14] and for POC in the ex vivo models [14]. Such endogenous CFTR activation 
would be brought about by some endogenous activators which are massively released during 
ischemia, such as ATP from the cardiomyocytes themselves [47, 48] and catecholamines 
from sympathetic nerve endings [49]. 
Myocardial cell death associated with I/R injury occurs by two different mechanisms, 
necrosis and apoptosis [13, 14, 50]. In the present study, the I/R injury in vivo was found to 
occur in parallel with increases in the level of serum CK-MB, an index of the necrotic injury 
of cardiomyocytes (Fig. 5), suggesting the loss of membrane integrity largely due to necrosis. 
In vitro experiments in cultured cardiomyocytes using a simulated I/R protocol also showed 
necrotic cell death characterized by PI stainability and the lack of an increase in caspase 3/7 
activity (Fig. 6). An activator of CFTR anion channels (genistein) reduced such necrotic cell 
damage, while a CFTR antagonist (CFTRinh-172) aggravated necrotic injury after I/R in vivo 
(Fig. 5) and after simulated I/R in vitro (Fig. 6). Since there remains a possibility that the CFTR 
activator and inhibitor exerted non-specific actions as well, the effects of overexpression and 
knockdown of CFTR gene were tested in the in vitro experiments. Transfection with cDNA 
or siRNA of CFTR into cultured cardiomyocytes was then found to ameliorate or aggravate, 
respectively, necrotic cell injury induced by hypoxia/reoxygenation (Fig. 7). Thus, it appears 
that the activity of cardiac CFTR exerts an anti-necrotic, but not anti-apoptotic, effect on I/R 
injury.
It is noted that myocardial necrosis is a complication, though rare, of cystic fibrosis that 
leads to sudden, unexpected and fatal cardiac arrest in infants; this was first reported in 
1945 [51], and various other cases have been reported thereafter [52]. Recently, it was also 
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reported that a 13-month old patient who died of heart failure with myocardial necrosis was 
retrospectively diagnosed after histological examination as having had cystic fibrosis [53]. 
Cell swelling is a prominent feature of ischemic myocardial injury, and is due to 
intracellular hypertonic stress in the myocytes resulting from accumulation of the by-
products of anaerobic metabolism. Even after reperfusion, irreversibly injured cells are 
known to exhibit enormous swelling [54]. This necrotic volume increase (NVI) is known to 
be associated with an impairment of the RVD mechanism in a number of pathophysiological 
situations [10]. Volume-sensitive outwardly rectifying anion channels (VSOR) are known 
to be activated by cell swelling and to be involved in the RVD process in a wide variety of 
cell types including cardiac myocytes [55]. VSOR activity was implicated in apoptotic injury 
caused by ischemia/reperfusion in myocardial cells [56, 57]. In the present study, however, 
an involvement of VSOR in necrotic injury induced by ischemia/reperfusion could be ruled 
out: necrotic injury was not augmented but reduced by genistein, which is an activator of 
CFTR but an inhibitor of VSOR [58, 59]. Wang et al. [9] reported that CFTR anion channels 
are activated by β-adrenergic stimulation and involved in the RVD that occurs after osmotic 
swelling in guinea pig cardiomyocytes. It is therefore conceivable that activation of CFTR 
anion channels plays an anti-necrotic role by facilitating the RVD process in cardiomyocytes 
subjected to ischemia/reperfusion. 
Chen et al. [13] reported that cardiac CFTR serves as a crucial mediator in mouse heart 
IPC on the basis of observations that the IPC-induced protection of mouse heart from I/R-
induced myocardial infarction was prevented by a CFTR blocker (gemfibrozil) and by targeted 
inactivation of the CFTR gene (CFTR−/− mice). Xiang et al. [14] recently provided evidence for 
a critical role of CFTR in IPC- and POC-mediated cardioprotection against I/R myocardial 
injury. The post-ischemic early reperfusion phase is a more relevant stage for therapeutic 
intervention than the stage prior to the ischemic attack, which is the target stage for IPC. 
Also, it must be noted that IPC and POC would not be practical as a therapeutic intervention 
for patients. In the present study, it was found that myocardial infarction was prominently 
reduced by CFTR activators administered by a post-ischemic intravenous infusion given for 
12 min from 10 min before to 2 min after reperfusion, but not by injection of the drugs 
10 min after starting reperfusion (Fig. 1). Thus, it is likely that the early reperfusion phase 
is the time window for therapeutic intervention, during which cardiac CFTR may be 
pharmacotherapeutically targeted to protect against myocardial infarction.
Conclusion
To test a possibility that activation of CFTR after ischemic attack can protect cardiac 
myocytes against I/R-induced myocardial injury, I/R experiments were performed in the 
hearts of WT and CFTR−/− mice in vivo and in rat ventricular myocytes without and with 
transfection of CFTR cDNA or siRNA in vitro. These experiments indicate that endogenous 
CFTR activity is involved in cardioprotection against necrotic I/R injury and that the 
administration of a CFTR activator after ischemic attack and in the early reperfusion phase 
may protect against necrotic myocardial injury induced by I/R. This study is the first to 
provide evidence that cardiac CFTR could be targeted by pharmacotherapeutic approaches 
even after an ischemic attack to protect against myocardial infarction.
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